A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab
Immune checkpoint inhibitors (ICIs) have become a focal point in cancer immunotherapy, though their utilization is also linked to the occurrence of diverse immune-related adverse events (irAEs). Herein, we present details of a 42-year-old woman diagnosed with a malignant vaginal melanoma who underwe...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2024/4662803 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849683507556646912 |
|---|---|
| author | Yonekazu Kidawara Manabu Kadoya Miki Kakutani-Hatayama Hidenori Koyama |
| author_facet | Yonekazu Kidawara Manabu Kadoya Miki Kakutani-Hatayama Hidenori Koyama |
| author_sort | Yonekazu Kidawara |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have become a focal point in cancer immunotherapy, though their utilization is also linked to the occurrence of diverse immune-related adverse events (irAEs). Herein, we present details of a 42-year-old woman diagnosed with a malignant vaginal melanoma who underwent ICI therapy with the combination of nivolumab and ipilimumab. Approximately two months after initiating therapy, the patient manifested destructive thyroiditis and fulminant type 1 diabetes mellitus, thus necessitating intensive insulin therapy. Following the onset of adrenocorticotropic hormone deficiency, frequent hypoglycemic episodes prompted the initiation of replacement therapy with hydrocortisone. Human leukocyte antigen (HLA)-DNA typing revealed the presence of HLA-DRB1∗04 : 05 and DQB1∗04 : 01. HLA-DR4 has been suggested to be associated with the development of multiple endocrine irAEs. This is the first reported case of three endocrine irAEs occurring within a short period, in which the presence of HLA-DR4 may have contributed to the pathogenesis. |
| format | Article |
| id | doaj-art-d6fa256405d247ce99dfc8700910a2ee |
| institution | DOAJ |
| issn | 2090-651X |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Endocrinology |
| spelling | doaj-art-d6fa256405d247ce99dfc8700910a2ee2025-08-20T03:23:51ZengWileyCase Reports in Endocrinology2090-651X2024-01-01202410.1155/2024/4662803A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and IpilimumabYonekazu Kidawara0Manabu Kadoya1Miki Kakutani-Hatayama2Hidenori Koyama3Department of DiabetesDepartment of DiabetesDepartment of DiabetesDepartment of DiabetesImmune checkpoint inhibitors (ICIs) have become a focal point in cancer immunotherapy, though their utilization is also linked to the occurrence of diverse immune-related adverse events (irAEs). Herein, we present details of a 42-year-old woman diagnosed with a malignant vaginal melanoma who underwent ICI therapy with the combination of nivolumab and ipilimumab. Approximately two months after initiating therapy, the patient manifested destructive thyroiditis and fulminant type 1 diabetes mellitus, thus necessitating intensive insulin therapy. Following the onset of adrenocorticotropic hormone deficiency, frequent hypoglycemic episodes prompted the initiation of replacement therapy with hydrocortisone. Human leukocyte antigen (HLA)-DNA typing revealed the presence of HLA-DRB1∗04 : 05 and DQB1∗04 : 01. HLA-DR4 has been suggested to be associated with the development of multiple endocrine irAEs. This is the first reported case of three endocrine irAEs occurring within a short period, in which the presence of HLA-DR4 may have contributed to the pathogenesis.http://dx.doi.org/10.1155/2024/4662803 |
| spellingShingle | Yonekazu Kidawara Manabu Kadoya Miki Kakutani-Hatayama Hidenori Koyama A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab Case Reports in Endocrinology |
| title | A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab |
| title_full | A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab |
| title_fullStr | A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab |
| title_full_unstemmed | A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab |
| title_short | A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab |
| title_sort | case in which hla dr4 is involved in the development of complex immune related endocrinological adverse events following combination therapy with nivolumab and ipilimumab |
| url | http://dx.doi.org/10.1155/2024/4662803 |
| work_keys_str_mv | AT yonekazukidawara acaseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab AT manabukadoya acaseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab AT mikikakutanihatayama acaseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab AT hidenorikoyama acaseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab AT yonekazukidawara caseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab AT manabukadoya caseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab AT mikikakutanihatayama caseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab AT hidenorikoyama caseinwhichhladr4isinvolvedinthedevelopmentofcompleximmunerelatedendocrinologicaladverseeventsfollowingcombinationtherapywithnivolumabandipilimumab |